# US 2010/0075983 A1 · D3 and 5-ht2a receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0075983 A1
- Document ID: US20100075983A1
- Status: Published application
- Kind: A1
- Application number: 12/560,459
- Filed: 2009-09-16
- Published: 2010-03-25
- Earliest claimed: 2008-09-22
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Luca Gobbi; Georg Jaeschke; Rosa Maria Rodriguez Sarmiento; Lucinda Steward
- Web page: https://patentgrep.com/patent/US20100075983A1

## CPC

- C07D 261/20: condensed with carbocyclic rings or ring systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 493/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds of the general formula (I) wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

## Claims

### Claim 1

A compound of formula (I):
wherein:
X is independently halogen or C1-6-alkyl;
n is 0, 1, or 2;
R1 is —COR2 or —SO2—C1-6-alkyl;
R2 is C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, C1-6-alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are each optionally substituted by one or more substituents selected from the group consisting of:
halo,
hydroxy,
C1-6-alkyl,
C1-6-haloalkyl,
C1-6-hydroxyalkyl,
C1-6-alkoxy,
C1-6-alkoxy optionally substituted by one or more Ra,
—S—C1-6-alkyl,
—SO2—C1-6-alkyl,
—CONH2,
—CHO,
3 to 10 membered cycloalkyl optionally substituted by one or more Ra,
4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra, and
5 to 10 membered heteroaryl optionally substituted by one or more Ra;
wherein Ra is selected from the group consisting of:
halo,
hydroxy,
C1-6-alkyl,
C1-6-hydroxyalkyl,
C1-6-haloalkyl, and
C1-6-alkoxy;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is —COR2.

### Claim 3 (depends on 1)

The compound of claim 1 having formula (I′):

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is —COR2.

### Claim 5 (depends on 1)

The compound of claim 1 having formula (Ia):
wherein:
R4 is hydrogen,
hydroxyl,
C1-6-alkyl,
C1-6-hydroxyalkyl,
C1-6-alkoxy,
3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or
4 to 7-membered heterocycloalkyl optionally substituted by one or more Rb,
wherein Rb is selected from the group consisting of:
hydroxy,
C1-6-alkyl,
C1-6-hydroxyalkyl, and
C1-6-alkoxy.

### Claim 6 (depends on 5)

The compound of claim 5 having formula (Ia′):

### Claim 7 (depends on 6)

The compound of claim 6 wherein R4 is C1-6-alkoxy or C1-6-alkoxy-C1-6-alkyl.

### Claim 8 (depends on 7)

The compound of claim 7 selected from the group consisting of:
N-trans-{4-[2-(4-benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-4,4-dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide; and
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide.

### Claim 9 (depends on 7)

The compound of claim 7 selected from the group consisting of:
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
3-Methoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
3-Methoxy-N-trans-(4-{2-[4-(5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide; and
2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide.

### Claim 10 (depends on 6)

The compound of claim 6 wherein:
R4 is 3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or
4 to 7-membered heterocycloalkyl optionally substituted by one or more Rb;
wherein Rb is selected from the group consisting of:
hydroxy,
C1-6-alkyl,
C1-6-hydroxyalkyl, and
C1-6-alkoxy.

### Claim 11 (depends on 10)

The compound of claim 10 selected from the group consisting of:
N-trans-{4-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
2-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(5-fluoro-benzo isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)—N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(1R,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-oxetan-3-yl)-acetamide; and
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-((S)-2,2,4-trimethyl-tetrahydro-pyran-4-yl-acetamide.

### Claim 12 (depends on 10)

The compound of claim 10 selected from the group consisting of:
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-((R)-2,2,4-trimethyl-tetrahydro-pyran-4-yl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-piperidin-1-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]ethyl}-cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-4-methyl-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide; and
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-hydroxy-cyclohexyl)-acetamide.

### Claim 13 (depends on 10)

The compound of claim 10 selected from the group consisting of:
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-oxetan-3-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]ethyl}-cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide; and
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide.

### Claim 14 (depends on 10)

The compound of claim 10 selected from the group consisting of:
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,4]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide; and
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide.

### Claim 15 (depends on 10)

The compound of claim 10 selected from the group consisting of:
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide; and
N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide.

### Claim 16 (depends on 1)

The compound of claim 1 having formula (Ib):
wherein:
R5 is 4 to 7-membered heterocycloalkyl; or
3 to 6-membered cycloalkyl optionally substituted by one or more halogen, hydroxyl or C1-6-alkoxy.

### Claim 17 (depends on 16)

The compound of claim 16 having formula (Ib′)

### Claim 18 (depends on 17)

The compound of claim 17 selected from the group consisting of:
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
Tetrahydro-furan-3-carboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
1-Hydroxy-cyclopropanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
(S)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
1-Chloro-cyclobutanecarboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
Cyclobutanecarboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide; and
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide.

### Claim 19 (depends on 1)

The compound according to claim 1, wherein the piperazinyl-ethyl moiety and the N-amide moiety are attached to the cyclohexyl-ring in a trans-configuration.

### Claim 20 (depends on 1)

The compound of claim 1, wherein X is fluoro or methyl.

### Claim 21 (depends on 1)

The compound of claim 1, wherein n is 1 or 2.

### Claim 22 (depends on 1)

The compound of claim 1, wherein R2 is C1-6-alkyl which is optionally substituted by one substituent selected from the group consisting of C1-6-alkoxy, —SO2—C1-6-alkyl and 6 membered heterocycloalkyl.

### Claim 23 (depends on 1)

The compound of claim 1, wherein R2 is methyl, methyl substituted by methanesulfonyl or [1,4]dioxin-2-yl or ethyl substituted by methoxy.

### Claim 24 (depends on 1)

The compound of claim 1 selected from the group consisting of:
N-trans-{4-[2-(4-benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-3-methoxy-propionamide;
N-trans-{4-[2-(4-benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-acetamide;
N-trans-{4-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-{4-[2-(4-Benzo[d]isoxazol-3-yl)-piperazin-1-yl)-ethyl]-cyclohexyl}-2-hydroxy-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
Tetrahydro-pyran-4-carboxylic acid-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide; and
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-3-methyl-butyramide.

### Claim 25 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-methanesulfonamide;
2-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-malonamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(1R,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]ethyl}-cyclohexyl)-2-(3-methyl-oxetan-3-yl)-acetamide; and
24(S)-2,2-Dimethyl-tetrahydro-pyran-4-yl)—N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide.

### Claim 26 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-((R)-2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-piperidin-1-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-4,4-dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide; and
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-rac-3,3,3-trifluoro-2-hydroxy-propionamide.

### Claim 27 (depends on 1)

The compound of claim 1 selected from the group consisting of:
Tetrahydro-furan-3-carboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-butyramide;
1-Hydroxy-cyclopropanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-4-methyl-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-hydroxy-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-hydroxy-cyclohexyl)-acetamide; and
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-3-methyl-butyramide.

### Claim 28 (depends on 1)

The compound of claim 1 selected from the group consisting of:
(S)—N-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-butyramide;
(S)-Tetrahydro-furan-3-carboxylic acid (4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohex yl)-2-oxetan-3-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3,3-trifluoro-propionamide;
4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide; and
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide.

### Claim 29 (depends on 1)

The compound of claim 1 selected from the group consisting of:
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-3-methyl-butyramide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide; and
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide.

### Claim 30 (depends on 1)

The compound of claim 1 selected from the group consisting of:
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
Ethanesulfonic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,4]dioxan-2-yl-acetamide; and
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-[1,3]dioxan-2-yl-acetamide.

### Claim 31 (depends on 1)

The compound of claim 1 selected from the group consisting of:
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methylsulfanyl-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;
3-Chloro-cyclobutanecarboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
5-Chloro-thiophene-2-carboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
5-Methoxy-thiophene-2-carboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-hydroxy-acetamide; and
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide.

### Claim 32 (depends on 1)

The compound of claim 1 selected from the group consisting of:
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methanesulfonyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methanesulfonyl-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-carbamic acid methyl ester;
Cyclobutanecarboxylic acid N-trans-(4-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3,3,3-trifluoro-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-amide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl-2-(tetrahydro-pyran-4-yl)-acetamide;
3-Methoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide; and
N-trans-(4-{2-[4-(6-Methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]ethyl}-cyclohexyl)-propionamide.

### Claim 33 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
3-Methoxy-N-trans-(4-{2-[4-(5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide;
2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide, and
N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide.

### Claim 34 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-(R)-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
2-(S)-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
(S)-4,4,4-Trifluoro-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-hydroxy-butyramide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-(tetrahydro-furan-2-yl)-acetamide; and
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-2-methoxy-propionamide.

### Claim 35 (depends on 1)

The compound of formula (I) according to claim 1 selected from the group consisting of:
2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-3-methoxy-propionamide; and
2-(R)-[1,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-1-yl]-ethyl}-cyclohexyl)-acetamide.

### Claim 36

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
wherein:
X is independently halogen or C1-6-alkyl;
n is 0, 1, or 2;
R1 is —COR2 or —SO2—C1-6-alkyl;
R2 is C1-6-alkyl, C1-6-haloalkyl, C1-6-hydroxyalkyl, C1-6-alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are each optionally substituted by one or more substituents selected from the group consisting of:
halo,
hydroxy,
C1-6-alkyl,
C1-6-haloalkyl,
C1-6-hydroxyalkyl,
C1-6-alkoxy,
C1-6-alkoxy optionally substituted by one or more Ra,
—S—C1-6-alkyl,
—SO2—C1-6-alkyl,
—CONH2,
—CHO,
3 to 10 membered cycloalkyl optionally substituted by one or more Ra,
4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra, and
5 to 10 membered heteroaryl optionally substituted by one or more Ra;
wherein Ra is selected from the group consisting of:
halo,
hydroxy,
C1-6-alkyl,
C1-6-hydroxyalkyl,
C1-6-haloalkyl, and
C1-6-alkoxy;
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
